Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

GP120: Target for Neutralizing HIV-1 Antibodies

GP120: Target for Neutralizing HIV-1 Antibodies Abstract The glycoprotein (gp) 120 subunit is an important part of the envelope spikes that decorate the surface of HIV-1 and a major target for neutralizing antibodies. However, immunization with recombinant gp120 does not elicit neutralizing antibodies against multiple HIV-1 isolates (broadly neutralizing antibodies), and gp120 failed to demonstrate vaccine efficacy in recent clinical trials. Ongoing crystallographic studies of gp120 molecules from HIV-1 and SIV increasingly reveal how conserved regions, which are the targets of broadly neutralizing antibodies, are concealed from immune recognition. Based on this structural insight and that from studies of antibody structures, a number of strategies are being pursued to design immunogens that can elicit broadly neutralizing antibodies to gp120. These include ( a ) the construction of mimics of the viral envelope spike and ( b ) the design of antigens specifically tailored to induce broadly neutralizing antibodies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Immunology Annual Reviews

GP120: Target for Neutralizing HIV-1 Antibodies

Loading next page...
 
/lp/annual-reviews/gp120-target-for-neutralizing-hiv-1-antibodies-0qQj907PzG

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Annual Reviews
Copyright
Copyright © 2006 by Annual Reviews. All rights reserved
ISSN
0732-0582
eISSN
1545-3278
DOI
10.1146/annurev.immunol.24.021605.090557
pmid
16551265
Publisher site
See Article on Publisher Site

Abstract

Abstract The glycoprotein (gp) 120 subunit is an important part of the envelope spikes that decorate the surface of HIV-1 and a major target for neutralizing antibodies. However, immunization with recombinant gp120 does not elicit neutralizing antibodies against multiple HIV-1 isolates (broadly neutralizing antibodies), and gp120 failed to demonstrate vaccine efficacy in recent clinical trials. Ongoing crystallographic studies of gp120 molecules from HIV-1 and SIV increasingly reveal how conserved regions, which are the targets of broadly neutralizing antibodies, are concealed from immune recognition. Based on this structural insight and that from studies of antibody structures, a number of strategies are being pursued to design immunogens that can elicit broadly neutralizing antibodies to gp120. These include ( a ) the construction of mimics of the viral envelope spike and ( b ) the design of antigens specifically tailored to induce broadly neutralizing antibodies.

Journal

Annual Review of ImmunologyAnnual Reviews

Published: Apr 23, 2006

There are no references for this article.